Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy
Post-surgical scarring is a known cause of trabeculectomy failure. The aim of this study was to investigate the effectiveness of ranibizumab as an adjuvant anti-scarring agent in experimental trabeculectomy. Forty New Zealand white rabbits were randomised into four eye treatment groups: groups A (co...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/8/7372 |
| _version_ | 1797605058171371520 |
|---|---|
| author | Yaakub Azhany Wan Faiziah Wan Abdul Rahman Hasnan Jaafar Jen Hou Low Wan Nazirah Wan Yusuf Ahmad-Tajudin Liza-Sharmini Jemaima Che Hamzah |
| author_facet | Yaakub Azhany Wan Faiziah Wan Abdul Rahman Hasnan Jaafar Jen Hou Low Wan Nazirah Wan Yusuf Ahmad-Tajudin Liza-Sharmini Jemaima Che Hamzah |
| author_sort | Yaakub Azhany |
| collection | DOAJ |
| description | Post-surgical scarring is a known cause of trabeculectomy failure. The aim of this study was to investigate the effectiveness of ranibizumab as an adjuvant anti-scarring agent in experimental trabeculectomy. Forty New Zealand white rabbits were randomised into four eye treatment groups: groups A (control), B (ranibizumab 0.5 mg/mL), C (mitomycin C [MMC] 0.4 mg/mL), and D (ranibizumab 0.5 mg/mL and MMC 0.4 mg/mL). Modified trabeculectomy was performed. Clinical parameters were assessed on post-operative days 1, 2, 3, 7, 14, and 21. Twenty rabbits were euthanised on day 7, and the other twenty were euthanised on day 21. Eye tissue samples were obtained from the rabbits and stained with haematoxylin and eosin (H&E). All treatment groups showed a significant difference in IOP reduction compared with group A (<i>p</i> < 0.05). Groups C and D showed a significant difference in bleb status on days 7 (<i>p</i> = 0.001) and 21 (<i>p</i> = 0.002) relative to group A. H&E staining showed significantly low fibrotic activity (<i>p</i> < 0.001) in group C on both days and inflammatory cell grade in group B on day 7 (<i>p</i> < 0.001). The grade for new vessel formation was significantly low in groups B and D on day 7 (<i>p</i> < 0.001) and in group D on day 21 (<i>p</i> = 0.007). Ranibizumab plays a role in reducing scarring, and a single application of the ranibizumab–MMC combination showed a moderate wound-modulating effect in the early post-operative phase. |
| first_indexed | 2024-03-11T04:55:44Z |
| format | Article |
| id | doaj.art-13bf1d29ebbc4d2b9136edabe599d523 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T04:55:44Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-13bf1d29ebbc4d2b9136edabe599d5232023-11-17T19:39:27ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-04-01248737210.3390/ijms24087372Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental TrabeculectomyYaakub Azhany0Wan Faiziah Wan Abdul Rahman1Hasnan Jaafar2Jen Hou Low3Wan Nazirah Wan Yusuf4Ahmad-Tajudin Liza-Sharmini5Jemaima Che Hamzah6Department of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Wilayah Persekutuan, MalaysiaDepartment of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, MalaysiaDepartment of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, MalaysiaDepartment of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, MalaysiaDepartment of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, MalaysiaDepartment of Ophthalmology & Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, MalaysiaDepartment of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Wilayah Persekutuan, MalaysiaPost-surgical scarring is a known cause of trabeculectomy failure. The aim of this study was to investigate the effectiveness of ranibizumab as an adjuvant anti-scarring agent in experimental trabeculectomy. Forty New Zealand white rabbits were randomised into four eye treatment groups: groups A (control), B (ranibizumab 0.5 mg/mL), C (mitomycin C [MMC] 0.4 mg/mL), and D (ranibizumab 0.5 mg/mL and MMC 0.4 mg/mL). Modified trabeculectomy was performed. Clinical parameters were assessed on post-operative days 1, 2, 3, 7, 14, and 21. Twenty rabbits were euthanised on day 7, and the other twenty were euthanised on day 21. Eye tissue samples were obtained from the rabbits and stained with haematoxylin and eosin (H&E). All treatment groups showed a significant difference in IOP reduction compared with group A (<i>p</i> < 0.05). Groups C and D showed a significant difference in bleb status on days 7 (<i>p</i> = 0.001) and 21 (<i>p</i> = 0.002) relative to group A. H&E staining showed significantly low fibrotic activity (<i>p</i> < 0.001) in group C on both days and inflammatory cell grade in group B on day 7 (<i>p</i> < 0.001). The grade for new vessel formation was significantly low in groups B and D on day 7 (<i>p</i> < 0.001) and in group D on day 21 (<i>p</i> = 0.007). Ranibizumab plays a role in reducing scarring, and a single application of the ranibizumab–MMC combination showed a moderate wound-modulating effect in the early post-operative phase.https://www.mdpi.com/1422-0067/24/8/7372modulation agentwound healingocular surgeryranibizumabtrabeculectomy |
| spellingShingle | Yaakub Azhany Wan Faiziah Wan Abdul Rahman Hasnan Jaafar Jen Hou Low Wan Nazirah Wan Yusuf Ahmad-Tajudin Liza-Sharmini Jemaima Che Hamzah Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy International Journal of Molecular Sciences modulation agent wound healing ocular surgery ranibizumab trabeculectomy |
| title | Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy |
| title_full | Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy |
| title_fullStr | Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy |
| title_full_unstemmed | Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy |
| title_short | Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy |
| title_sort | clinical and histopathological effects of intracameral ranibizumab in experimental trabeculectomy |
| topic | modulation agent wound healing ocular surgery ranibizumab trabeculectomy |
| url | https://www.mdpi.com/1422-0067/24/8/7372 |
| work_keys_str_mv | AT yaakubazhany clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT wanfaiziahwanabdulrahman clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT hasnanjaafar clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT jenhoulow clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT wannazirahwanyusuf clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT ahmadtajudinlizasharmini clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy AT jemaimachehamzah clinicalandhistopathologicaleffectsofintracameralranibizumabinexperimentaltrabeculectomy |